Suscríbete al boletín semanal

Suscríbete para recibir cada semana el boletín SINC con los contenidos más relevantes y no te pierdas nada de la actualidad científica.

Suscríbete al boletín semanal
If you are registered

You will not be able to connect if you exceed ten failed attempts.

If you are not yet registered

The SINC Agency offers different services depending on your profile.

Select yours:

Journalists Institutions
If you are registered

You will not be able to connect if you exceed ten failed attempts.

If you are not yet registered

The SINC Agency offers different services depending on your profile.

Select yours:

Journalists Institutions
The compound will enter the clinical trial phase at the end of 2018

A drug to treat retinal diseases with drops instead of injections

The Spanish firm Sylentis has developed a compound to treat diseases of the retina, such as age-related macular degeneration and diabetic retinopathy, which will be administered by ophthalmic drops instead of intraocular injections. The drug, which has been tested in animals, is a small interfering RNA capable of penetrating the cells of the retina and blocking the formation of new blood vessels.

Sylentis SYL136001v10 drug is a small interfering RNA capable of penetrating the cells of the retina and blocking the formation of new blood vessels by intravitreal drops. / PharmaMar

A new compound, developed by the biotechnology company Sylentis, is able to penetrate the retina to treat age-related macular degeneration and diabetic retinopathy, simply with the administration of ophthalmic drops.

The drug is a small interfering RNA capable of penetrating the cells of the retina and blocking the formation of new blood vessels

The drug SYL136001v10, presented by the PharmaMar group company, is still in the preclinical phase. “Its effectiveness has been proven in animal models and trials with humans will begin at the end of 2018”, said Covadonga Pañeda, R+D Manager at Sylentis.

Pañeda is the main author of a study on SYL136001v10, which was presented at the end of September at the XIII Annual Meeting of the Oligonucleotides Therapeutics Society, held in Bordeaux (France).

Objective: to silence the expression of the NRARP protein

Pañeda goes on to explain that this compound “is a small interfering RNA (siRNA) designed to silence the expression of NRARP, a protein that controls the formation of new blood vessels in the retina”.

Covadonga Piñeda, main author of the study and R&D manager director at Sylentis. / PharmaMar

In this way, she says, “the drug exerts its action by entering the cells of the retina, where it prevents the synthesis of this protein and blocks the formation of new vessels, which is one of the fundamental characteristics of degenerative diseases of the retina”.

The compounds currently used to treat these diseases are based on large antibodies that cannot penetrate from the ocular surface to the retina, so they must be administered by intravitreal injections.

Therefore, “patients suffering from age-related macular degeneration or diabetic retinopathy have to go to the hospital where the treatments are performed with ocular injections, which is annoying and painful, and also involves a significant financial investment for the health system”, says Covadonga Pañeda.

Until now, macular degeneration and diabetic retinopathy are treated with intravitreal injections

Efficacy in animal models

However, she notes, "siRNA, like SYL136001v10, are up to 10 times smaller than these treatments. Their size allows them to penetrate the retina and inhibit the formation of new blood vessels after their application in ophthalmic drops, as we have shown in animal models”.

In particular, “efficacy studies have shown that the reduction of NRARP in the retina by means of siRNA leads to the regression of angiogenic retinal lesions and that the observed reductions are equivalent to those of anti-VEGF, which is the current treatment standard for these diseases with ocular injections”, stresses the R&D manager. .

The firm, located in Tres Cantos (Madrid), plans to take charge of the first clinical efficacy studies. Once the proof of concept in humans has been demonstrated, it will try to license the drug to a multinational.

Reference:

Covadonga Pañeda et al.“Targeting NRARP with siRNA based compounds for the treatment of retinal neovascularization”.Annual Meeting of the Oligonucleotide Therapeutics Society (September 2017).

Source: SINC
Copyright: Creative Commons
Related articles
Alt de la imagen
Shrimp shells to produce electrodes for large storage batteries

Spanish researchers at MIT have developed a system to produce electrodes for vanadium flow batteries, used in renewable energy storage. The electrodes are made from chitin, a polysaccharide found in the exoskeleton of crustaceans and insects. The advantage of this component is that it contains nitrogen in addition to carbon, which is then incorporated into the structure of the electron during the production process, improving electrode’s performance.

Alt de la imagen
Graphene for remote wound monitoring

French scientists at the Neel Institute have produced a graphene patch that records the condition of chronic wounds, such as ulcers suffered by the elderly or those with diabetes, at any time. The data can be sent from home to the hospital via mobile phone, facilitating a rapid response to possible infections.